Clinical Trial

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

A breakthrough test for Parkinson's is expanding worldwide, promising earlier, more accurate diagnoses and accelerating the hunt for a cure.

AskBio completes enrollment for a pivotal Phase 2 trial of a one-time gene therapy, potentially revolutionizing treatment for millions with heart failure.

Abbisko's irpagratinib gets EMA Orphan Drug status, fast-tracking a precision therapy for a hard-to-treat liver cancer subgroup with unmet needs.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Final trial data shows pralsetinib offers years of survival for RET+ lung cancer, but realizing its full potential hinges on overcoming diagnostic hurdles.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.

The biotech firm's oversubscribed funding round will accelerate its universal flu shot and a diverse pipeline targeting cancer, malaria, and Alzheimer's.

Phase 2 data for HRS/BHB-1893 show rapid efficacy and a simplified regimen, signaling a potential new era for treating hypertrophic cardiomyopathy.

HistoSonics begins a landmark trial for a non-invasive BPH therapy that uses focused ultrasound to mechanically destroy tissue without incisions or heat.

An amended deal with Tasly positions AP Biosciences to license its innovative bispecific cancer therapy to global pharma giants, targeting a lucrative market.

Japanese pharma giant Meiji Seika Pharma backs Centivax's quest for a universal flu vaccine, a move that could revolutionize global pandemic preparedness.

Neumora reveals promising data for Alzheimer's and schizophrenia drugs, but a delay in its obesity program highlights the high-stakes world of biotech.